Navigation Links
Buffalo Heart Group Investigates Early Heart Attack Detection Device Developed By Angel Medical Systems
Date:11/29/2011

BUFFALO, N.Y., Nov. 29, 2011 /PRNewswire/ -- Buffalo Heart Group, LLP, 2011:  Today Dr. ZakiMasud, Kaleida Health, Buffalo, NY announced its first implant of the AngelMed Guardian cardiac monitor and alert system. The system is designed to reduce the time it takes patients to get to the emergency room during an impending heart attack.  Dr. Hashmat Ashraf, performed the first implant in the state of New York, and is among the very first physicians across the United States to implant the experimental device.

(Photo: http://photos.prnewswire.com/prnh/20111129/NY13888 )

The AngelMed Guardian system is designed to track significant changes in the heart's electrical signal and then alert patients to seek medical attention.  The objective of the ALERTS Pivotal Study is to provide an assessment of the safety and effectiveness of the AngelMed Guardian System.

David Garland, a 7th grade teacher at JFK in Buffalo, NY is the first patient in New York enrolled in the ALERTS study to receive the AngelMed Guardian System.  David had a heart attack in July and underwent stent placement.  He has a strong family history of heart disease; his symptoms included fatigue and "indigestion like" pain and had symptoms for weeks before his heart attack.

David Garland was successfully implanted with the device by Dr. Ashraf of Kaleida Health Millard Fillmore Gates Hospital.

Quote from Principal Investigator:  "This study provides an excellent opportunity for some of our patients who are at high-risk of having another heart attack. The device is designed to measure changes in the electrical signal of the heart and alert the patient at the earliest onset of a heart attack so that they can get treatment as soon as possible."

According to the American Heart Association, one of every five deaths in the US is attributable to coronary heart disease. Furthermore, 50% of heart-attack fatalities occur within one hour of symptom onset and occur before the patient even reaches the hospital.

The AngelMed Guardian System is comprised of an internal implantable device about the size of a standard pacemaker with a lead into the heart, an external telemetry device, and a programmer that aids physicians in evaluating heart signals.

Buffalo Heart Group is among the first medical facilities to participate in the AngelMed Guardian system trial. To participate in the ALERTS study, patients must meet various inclusion criteria. For more information on the AngelMed Guardian system or the ALERTS study protocol, contact: Marcia Makoviecki of Angel Medical Systems @ (732) 542-5551 x205

Forward Looking Statements: Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes or benefits are forward-looking statements. A number of risks and uncertainties such as risks associated with product development and commercialization efforts, results of clinical trials, ultimate clinical outcomes and benefit of the Company's products to patients, market and physician acceptance of the products, intellectual property protection and competitive product offerings could cause actual events to adversely differ from the expectations indicated in these forward looking statements.


'/>"/>
SOURCE Angel Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. I-Flow Corporation Enters into Exclusive Government Distribution Agreement With Buffalo Supply, Inc.
2. Many Heart Attack Patients Dont Get Best Emergency Treatment
3. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
4. American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?
5. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
6. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
7. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
8. Its Only Heartburn...or is it? Chronic Heartburn a Risk Factor for Precursor to Esophageal Cancer
9. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
10. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
11. Terumo Heart Reports Summary of DuraHeart(TM) LVAS Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... WOONSOCKET, R.I. , Feb. 10, 2016  CVS ... vaccines to people living in Santa Clara ... of Meningitis B on the Santa Clara University campus. ... vaccines available to protect patients against the disease. Students ... are encouraged to get vaccinated. In addition, anyone who ...
(Date:2/10/2016)... Feb. 10, 2016  Oxis International Inc. (OTC/QB: OXIS) ... was described as a "clinical trial triumph" after one ... into complete cancer remission. Daniel Vallera ... Masonic Cancer Center. --> Daniel Vallera ... Masonic Cancer Center. --> An article ...
(Date:2/10/2016)... 2016  LexisNexis® Risk Solutions, a leading provider ... launch of LexisNexis Provider Performance Monitor , ... and optimize the quality and efficiency of provider ... scores. By measuring provider performance through Provider Performance ... better outcomes, improve the patient experience and reduce ...
Breaking Medicine Technology:
(Date:2/10/2016)... Calif. (PRWEB) , ... February 10, 2016 , ... ... Water Brand. There were three leading bottled water brand owners that topped the list ... that enhance connectivity and optimize conversion. The premier brand was Tibet 5100, a top ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... bring together more than 200 of the country’s top healthcare executives to share ... “The true benefit of the Forum is the provider-centric perspective, experience, expertise and ...
(Date:2/10/2016)... ... ... Armune BioScience signed a definitive agreement with ARCpoint Labs ... country. Launched in April of 2015, Apifiny is the only cancer specific, non-PSA blood ... exceeded 3,000 tests in 2015. Primary care physicians and urologists have utilized Apifiny to ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... the Ohio Safety Congress and Expo event March 9-11, 2016. Hosted by Ohio's ... Convention Center. , As the longest running and largest worker's compensation event ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... Drive, Jacksonville, FL 32224, February 26th: Amateur & Professional Divisions - Time: ... Time: 7:00pm – 10:00pm | Ticket Prices $30, Social Media: http://www.USPoleSportsFed.org ...
Breaking Medicine News(10 mins):